logo-loader
viewStarpharma Holdings Limited

Starpharma soars on “very exciting” ovarian cancer results

Starpharma are already up 24%, in Australia, after its potential treatment outperformed existing drugs in a model

drug_research,_hicroscope,_sized_5649d1462751c.png
Model results show improved anticancer effectiveness and survival

Starpharma (OTCMKTS:SPHRY, ASX:SPL) looks set to soar in early deals in New York after it revealed were described as “very exciting” results from the ongoing development of a potential ovarian cancer drug.

The company’s candidate – described as an antibody-targeted DEP conjugate – in an ovarian cancer model significantly outperformed existing therapies, it said.

In the model, the DEP conjugate showed complete tumour regression and 100% survival, Starpharma told investors.

The experiments results show both improved anticancer effectiveness and survival compared to Roche’s Kadcyla and Herceptin, it added.

“We are very excited by these latest results for our targeted DEP™ conjugates and feedback from commercial parties on this new data has been very positive indeed,” it said in a statement.

The company added that talks are currently underway with a number of pharmaceutical companies regarding its targeted DEP conjugate and its technology platform.

In Sydney, where the company is also listed, the shares gained 1.74 Australia cents or 24% to trade at 90 cents each.

Quick facts: Starpharma Holdings Limited

Price: 1.19 AUD

ASX:SPL
Market: ASX
Market Cap: $443.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium outlines key goals for 2020 and strategic agreement with...

Australian Vanadium Ltd (ASX:AVL) managing director Vincent Algar updates Proactive on expectations for the vanadium market in 2020, and key goals for the company in the year ahead, including determining and confirming strategic funding partners. The MD recently returned from a trip to China...

12 minutes ago

2 min read